KyooBe Tech
KyooBe Tech GmbH is a German pharmaceutical manufacturing technology company, spun out of Bausch+Ströbel in 2020, that builds LEEI-based hardware systems (eFIT, MOSAIC) for chemical-free pathogen inactivation in vaccine manufacturing and automated cell and gene therapy production, serving enterprise pharma and biotech manufacturers.
- Company typePrivate
- Founded2020
- HeadquartersLeinfelden-echterdingen, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What KyooBe Tech does
KyooBe Tech GmbH is a German pharmaceutical manufacturing technology company founded in January 2020 as a spin-off of Bausch+Ströbel SE + Co. KG and headquartered in Leinfelden-Echterdingen, Baden-Württemberg. The company commercializes Low Energy Electron Irradiation (LEEI), a proprietary physical method that uses low-energy electron beams to inactivate pathogens in liquid solutions within sub-second exposure times while preserving antigenic structures, positioning it as a chemical-free alternative to formaldehyde and beta-propiolacton used in traditional vaccine manufacturing.
The company's product portfolio centers on three hardware platforms: eFIT, a product series for high-speed (≤1 second) pathogen inactivation with demonstrated 6-log pathogen reduction and GMP-compliant design, targeted at human and veterinary vaccine manufacturers; INACTIVATE, the underlying industrial and small-scale pathogen inactivation technology; and MOSAIC, a modular cube-based matrix high-rack automation platform for fully automated, GMP-compliant personalized cell and gene therapy manufacturing covering enrichment, isolation, activation, gene transfer, expansion, and formulation. The technology is backed by the ELVIRA patent family filed in 2014 and developed through the LEEI Consortium with four Fraunhofer institutes (FEP, IGB, IPA, IZI).
KyooBe Tech monetizes through capital equipment sales of eFIT Lab and industrial-scale systems under custom multi-year contracts, complemented by feasibility-study-as-a-service engagements using the eFIT Lab unit to qualify enterprise customers. Distribution combines a direct enterprise sales motion — supported by an active conference presence at CPHI, ISCT, PDA, and the World Vaccine Congress — with access to Bausch+Ströbel's global pharmaceutical equipment distribution and service network, including its sister company WILCO AG. The primary customer segments are enterprise pharmaceutical vaccine manufacturers and cell and gene therapy manufacturers, with a secondary addressable segment in blood product processing.
KyooBe Tech firmographics
Firmographics- Name
- KyooBe Tech
- Legal name
- KyooBe Tech GmbH
- Website
- https://kyoobe.tech
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- KyooBe Tech GmbH is a German pharmaceutical manufacturing technology company, spun out of Bausch+Ströbel in 2020, that builds LEEI-based hardware systems (eFIT, MOSAIC) for chemical-free pathogen inactivation in vaccine manufacturing and automated cell and gene therapy production, serving enterprise pharma and biotech manufacturers.
- Ownership category
- akta.pro rank
KyooBe Tech industry classification
Industry- Product category
- Bioprocess Manufacturing Equipment
- NAICS
- Irradiation Apparatus Manufacturing (334517)
- SIC
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)
Keywords
Where KyooBe Tech is headquartered
LocationHeadquarters
- HQ city
- Leinfelden-echterdingen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
KyooBe Tech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- eFIT Systems — Hardware Sales: KyooBe Tech sells its eFIT Lab and eFIT industrial-scale pathogen inactivation systems to pharmaceutical manufacturers. These are specialized capital equipment units for vaccine R&D, cell therapeutics manufacturing, and contamination control. Pricing is not publicly disclosed and likely varies by configuration and scale.
- Feasibility Studies as a Service: KyooBe Tech offers expert feasibility studies using the eFIT Lab unit, allowing customers to test pathogen suspensions, virus suspensions, blood-derived products, and various media/supplements. This generates service revenue while also driving adoption of the eFIT hardware platform.
- MOSAIC Automation Platform: KyooBe Tech is developing the MOSAIC modular automation platform for cell and gene therapy manufacturing. Revenue model anticipated as hardware/production system sales to pharma manufacturers of personalized therapeutics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quotation — eFIT Lab and eFIT industrial-scale systems |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
KyooBe Tech product offering
Product offeringCore offering
The input does not contain source-supported details on KyooBe Tech's core offering beyond unverified references to Low Energy Electron Irradiation (LEEI) technology, pathogen inactivation systems for vaccine manufacturing, and modular automation platforms for cell and gene therapy production.
Product overview
KyooBe Tech is a pharmaceutical manufacturing technology company offering a portfolio of hardware-based systems for vaccine production and cell/gene therapy manufacturing. The core offerings include: (1) eFIT - a product series for high-speed pathogen inactivation using Low Energy Electron Irradiation (LEEI) technology for vaccine and cell therapy applications; (2) INACTIVATE - industrial-scale pathogen inactivation technology using electron beam; and (3) MOSAIC - a modular, fully automated platform for cell and gene therapy manufacturing with GMP-compliant independent units. The company operates as a spin-off of Bausch+Ströbel, leveraging LEEI technology developed in partnership with Fraunhofer research institutes.
Differentiator
Problem solved
Functional benefit
Brands
- eFIT: Revolutionary product series for inactivation of pathogens in pharmaceutical production processes using low-energy electron irradiation (LEEI). Features lightning-fast inactivation (≤ 1s), scalable throughput, and chemical-free operation.
- MOSAIC
- INACTIVATE
- eFIT Lab Platform
Quantifiable outcome
- Pathogen inactivation time reduced to <1 second (vs. hours/days for chemical methods)
- +3 more outcomes
Companies that use KyooBe Tech
Customer profileNamed customers2 records
Segments3 records
KyooBe Tech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
KyooBe Tech partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship / core and minor.
- Bausch+Ströbel SE + Co. KGflagship / coreKyooBe Tech was founded as a spin-off by Bausch+Ströbel in January 2020. B+S is the parent company and primary strategic partner, contributing over 56 years of experience in pharmaceutical filling, packaging, and inspection systems. B+S provides global distribution capabilities, GMP-compliant manufacturing expertise, and access to its established customer network. KyooBe Tech operates as an independent company within the B+S Group, which also includes WILCO AG. The partnership was formalized through a licensing deal between Fraunhofer and Bausch+Ströbel in January 2019.
- Fraunhofer-Gesellschaft (Institutes: FEP, IGB, IPA, IZI)flagship / coreFour Fraunhofer institutes (FEP, IGB, IPA, IZI) form the scientific foundation of the LEEI Consortium. They have collaborated since 2012 on LEEI research, including first virus inactivation experiments (2012), filing of the ELVIRA patent family (2014), and prototype development (ELLI 300, ELLI 2.0). Fraunhofer FEP and IPA jointly developed the automated irradiation system, with experimental base installed at Fraunhofer IZI in Leipzig. Fraunhofer IZI leads vaccine development and animal trials with a BSL-2 laboratory LEEI system. KyooBe Tech was spun off in 2020 specifically to commercialize Fraunhofer-developed LEEI technology.
- WILCO AGminorWILCO AG is a Swiss solution provider of leading inspection systems serving the pharmaceutical, biotech, diagnostic, medical device, and packaging industry worldwide. With 50 years of tradition in innovation, they offer leak detection (CCIT) and visual inspection solutions. WILCO AG is part of the B+S Group ecosystem.
Scale indicators3 records
Recent moves8 records
Expansion highlights6 records
KyooBe Tech competitors and assessment
Company assessmentDirect peers
- STERIS: Global sterilization, disinfection, and lab equipment provider including gamma, X-ray, and electron beam sterilization systems used in pharma manufacturing. Overlaps with KyooBe in irradiation-based processing and contamination control for pharmaceutical and medical-device manufacturers.
- Cerus Corporation: Markets the INTERCEPT blood pathogen inactivation system (amotosalen + UVA) for blood platelets and plasma. Closest direct competitor to KyooBe's eFIT in pathogen inactivation, addressing overlapping bioprocessing and blood-product customers with a different (photochemical) but similarly regulatory-driven platform.
- Bausch+Ströbel: Parent company of KyooBe Tech and a 56-year veteran manufacturer of pharmaceutical filling, packaging, and inspection systems. Directly comparable as both an OEM partner and a sister-line competitor serving the same vaccine/ATMP manufacturers with adjacent capital equipment.
- IBA Industrial: Provider of electron beam and X-ray industrial accelerators for sterilization, food safety, and material processing. Highly relevant technology peer to KyooBe's low-energy electron irradiation platform, serving pharma and biotech applications with established industrial-scale equipment.
- Terumo BCT: Provides the Mirasol pathogen reduction technology system for blood components. Comparable to KyooBe in addressing pathogen inactivation for biological products with a different light-based chemistry, competing for the same blood-bank and biopharma QA customers.
Broad incumbents
- Sartorius: Major bioprocess equipment and consumables supplier for vaccine, cell therapy, and gene therapy manufacturers. Overlaps with KyooBe on the MOSAIC side as an incumbent in upstream/downstream bioprocessing, though Sartorius does not offer a direct eFIT-equivalent pathogen inactivation system.
- Getinge: Global medtech and life-science company providing sterilization, infection control, and pharmaceutical processing equipment. Comparable to KyooBe in the pharma-manufacturing-capex category and contamination-control/sterilization use cases.
- Hitachi High-Tech (Industrial Systems): Supplies industrial electron beam systems for sterilization, materials modification, and pharma applications through Hitachi's industrial portfolio. Comparable technology peer to KyooBe in electron-beam-based processing for industrial customers.
- Cytiva (Danaher): Global bioprocess and ATMP manufacturing platform provider under Danaher, including cell-therapy automation and viral-vector production tools. Broad incumbent peer in the same pharmaceutical manufacturing equipment categories KyooBe targets with MOSAIC and eFIT.
- Syntegon (formerly Bosch Packaging Technology): Large-scale supplier of processing and packaging machinery for the pharmaceutical industry, including fill-finish and inspection systems. Sister-industry incumbent to Bausch+Ströbel/KyooBe, addressing the same vaccine and biopharma manufacturers with a broader portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
KyooBe Tech social profiles
Digital presenceKyooBe Tech financial estimates
Financial estimateRevenue estimate
Valuation estimate
KyooBe Tech leadership team
Management profileNumber of profiles
KyooBe Tech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KyooBe Tech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KyooBe Tech
What does KyooBe Tech do?
The input does not contain source-supported details on KyooBe Tech's core offering beyond unverified references to Low Energy Electron Irradiation (LEEI) technology, pathogen inactivation systems for vaccine manufacturing, and modular automation platforms for cell and gene therapy production.
Is KyooBe Tech a public or private company?
KyooBe Tech is a private company. It is classified as unknown and is currently operating.
When was KyooBe Tech founded?
KyooBe Tech was founded in 2020. It employs 11 to 50 people.
Where is KyooBe Tech based?
KyooBe Tech is headquartered in Leinfelden-echterdingen, Germany, in the Europe region.
How does KyooBe Tech make money?
Three revenue lines are on record. eFIT Systems — Hardware Sales are the primary driver. The others are feasibility Studies as a Service and MOSAIC Automation Platform.
Who are KyooBe Tech's main competitors?
Direct peers on record are STERIS, Cerus Corporation, Bausch+Ströbel, IBA Industrial and Terumo BCT. Broad incumbents are Sartorius, Getinge, Hitachi High-Tech (Industrial Systems), Cytiva (Danaher) and Syntegon (formerly Bosch Packaging Technology).
Does KyooBe Tech have an API?
No public API is recorded for KyooBe Tech.
What industry is KyooBe Tech in?
KyooBe Tech's product category is Bioprocess Manufacturing Equipment. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 334517 and its SIC code is 3844.